Cabozantinib is a multi-tyrosine kinase inhibitor (TKI) of MET, AXL, RET, and VEGFR2 which reduces tumor growth, metastasis, and angiogenesis and is approved for use in patients with advanced RCC9–11. Here, KDR is linked to neoplasm.